INTRODUCTION

Thoracic artificial lungs (TALs) are being developed as a treatment for acute respiratory failure and as a bridge to lung transplantation. In vivo experiments with TALs have demonstrated gas transfer rates capable of nearly full support of adult humans for up to seven days [1,2]. Despite the success in respiratory support, all current TALs possess higher impedances than the natural pulmonary circulation, and in vivo testing of these devices has led to cases of increased right ventricular hydraulic power output and right ventricular dysfunction [1,3,4]. These experiments have all been performed with either healthy animals or animals with, at worst, acute lung failure and near normal pulmonary hemodynamics. Clinically, these devices will be used with patients with a wide variety of disease states and pulmonary hemodynamics. All patients will possess some degree of pulmonary hypertension. For some, the hypertension may be long-term and accompanied by right ventricular dysfunction, making it more difficult for the right ventricle (RV) to support increased workloads without a significant reduction in cardiac output (CO). Thus, a means is required to pre-operatively assess a patient to ensure that TAL implantation does not cause a deleterious decrease in CO.

Right ventricular function is predominantly affected by natural and artificial lung resistances; the TAL attachment mode, in series or parallel; and the percentage of the CO going to the artificial lung. Clinically, the natural and artificial lung resistances will be fixed, whereas the attachment mode and percentage of CO going to the TAL can be varied to maintain proper RV function. In-parallel attachment can reduce the overall pulmonary system resistance (PSR) and work requirements of the RV and lead to improved RV function. Some blood, however, bypasses the natural lungs, limiting performance of their non-respiratory functions and possibly allowing passage of harmful emboli to the systemic circulation. In-series attachment has the advantage that the entire CO flows through the natural lungs, allowing for filtration and performance of non-respiratory functions. In-series attachment, however, increases the overall PSR and RV power requirements, and this increase is proportional to the percentage of CO going to the TAL.

The effect of PSR on RV function make it desirable to have a pre-operative means to determine which TAL attachment mode is ideal for each patient. We are currently examining four possible indices for predicting the ideal attachment mode: maximum right ventricular output power (RVOP), maximum cardiac index (CI), RVOP reserve, and CI reserve. These indices have several advantages over contractility measurements in the prediction and assessment of RV function during TAL implantation. First, unlike contractility, they are good relative and absolute measurements [5] and can be compared between patients and to numerical models of the pulmonary circulation with or without a TAL. Second, the left ventricle’s ability to generate flow or power increases with the health of a heart [5, 6], and this may also hold true for the right ventricle. Dobutamine-induced, maximum average left ventricular output power has been used successfully to predict survival of patients with left ventricular failure with greater than 87% accuracy [5,7]. Both maximum RVOP and CI can be determined through progressive stimulation of the heart by dobutamine while measuring real-time PA flow and pressure. As dobutamine infusion rates increase, CI and RVOP rise, reach a plateau, and then fall. We believe the peak and reserve values of both may be predictive of the RV’s reaction to elevated PSR.

METHODS

Two groups are proposed to determine if pre-implantation, dobutamine-induced RVOP or CI can be used to predict the effect of elevated PSR on right ventricular function. The first group consists of healthy sheep with three different treatments: in-parallel implantation, in-series implantation, or pulmonary artery banding. The second group consists of sheep with simulated, long-term, respiratory disease with the same three treatments. In these sheep, 50 g of sephadex G-50 beads were injected into the pulmonary circulation over the course of one year. The beads lodge within the pulmonary arterioles, blocking flow and leading to increased pulmonary resistance. The initial studies reported here include six animals. Two sheep are healthy with a TAL.
RESULTS AND DISCUSSION

Cardiac indices were found to decrease linearly with PSR in each sheep when cardiac indices were below normal, healthy values (CI < 0.098 L/min/kg). The PSR change to reach any given CI could thus be determined using this linear relationship. Graphs of the various RV performance indices vs. this PSR change indicate that peak CI is the only index capable of effectively predicting the PSR change required to reach a given CI. Figure 1 shows the PSR change that would bring each sheep to a CI of 0.075 L/min/kg. In these initial results, any sheep with a peak CI greater than 0.15 should be able to tolerate some degree of in-series attachment, and those at or below this level should be implanted in parallel instead. The percentage of CO that can safely flow through the TAL can then be determined by calculating the resistance changes using simple electrical circuit analogues. Therefore, initial results suggest that pre-operative determination of peak CI could be an effective method of determining which attachment modes is ideal for a given patient.

REFERENCES


ACKNOWLEDGEMENTS

This work was supported by American Heart Association Scientist Development Grant Number 0235439Z.

The authors would like to thank those who assisted in data analysis: Alexander Kuo, Jesse Moore, Keith Pennington, Royi Razi, Qasim Reza, and Bhoomika Rawat.